Evidence map›Paper›PMID 39559990›Full record

Trial reportEmerging microbes & infections2025

Evaluation of waning of IgG antibody responses after rVSVΔG-ZEBOV-GP and Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccines: a modelling study from the PREVAC randomized trial.

Simon Valayer, Marie Alexandre, Mélanie Prague, Abdoul Habib Beavogui, Seydou Doumbia, Mark Kieh, Brian Greenwood, Bailah Leigh, Marie Poupelin, Christine Schwimmer and 12 more

Abstract readRandomized Controlled TrialClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Emerging microbes & infections, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Simon ValayerInfection, Antimicrobials, Modelling, Evolution (IAME), Université Sorbonne Paris Nord, Paris, France; Université Sorbonne Paris Cité, Institut national de la santé et de la recherche médicale (Inserm), Paris, France; Bordeaux Population Health Research Centre, Université de Bordeaux, Inserm, and Inria, Bordeaux, France.
Marie AlexandreBordeaux Population Health Research Centre, Université de Bordeaux, Inserm, and Inria, Bordeaux, France; Vaccine Research Institute, Faculté de Médicine, Université Paris-Est Créteil, Créteil, France.
Mélanie PragueBordeaux Population Health Research Centre, Université de Bordeaux, Inserm, and Inria, Bordeaux, France; Vaccine Research Institute, Faculté de Médicine, Université Paris-Est Créteil, Créteil, France.
Abdoul Habib BeavoguiCentre National de Formation et de Recherche en Santé Rurale (CNFRSR) de Mafèrinyah, Ministère de la Santé et de l'Hygiène Publique Mafèrinyah, Guinea.
Seydou DoumbiaUniversity Clinical Research Center, University of Sciences, Technique and Technology of Bamako, Bamako, Mali.
Mark KiehPartnership for Research on Ebola Virus in Liberia (PREVAIL), Monrovia, Liberia.
Brian GreenwoodLondon School of Hygiene & Tropical Medicine (LSHTM), London, UK.
Bailah LeighCollege of Medicine and Allied Health Sciences (COMAHS), University of Sierra Leone, Freetown, Sierra Leone.
Marie PoupelinBordeaux Population Health Research Centre, Université de Bordeaux, Inserm, and Inria, Bordeaux, France.
Christine SchwimmerEuropean Clinical Trials Platform & Development (EUCLID), Université de Bordeaux, Centre Hospitalier Universitaire Bordeaux, and Inserm, ISPED, Bordeaux, France.
Samba O SowCentre pour le Développement des Vaccins, Ministère de la Santé et du Développement Social du Mali, Bamako, Mali.
Irina Maljkovic BerryIntegrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Frederick, MD, USA.
Jens H KuhnIntegrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Frederick, MD, USA.
Daniela FuscoFrench Agency for Research on AIDS and Viral Hepatitis (ANRS), Emerging Infectious Diseases, PariSanté Campus, Paris, France.
Natasha Dubois CauwelaertInserm, Cedex 13, Paris, France.
Deborah Watson-JonesLondon School of Hygiene & Tropical Medicine (LSHTM), London, UK.
Rodolphe ThiébautBordeaux Population Health Research Centre, Université de Bordeaux, Inserm, and Inria, Bordeaux, France.
Yves LévyVaccine Research Institute, Faculté de Médicine, Université Paris-Est Créteil, Créteil, France.
Yazdan YazdanpanahInfection, Antimicrobials, Modelling, Evolution (IAME), Université Sorbonne Paris Nord, Université Sorbonne Paris Cité, and Institut national de la santé et de la recherche médicale (Inserm), Paris, France.
Laura RichertBordeaux Population Health Research Centre, Université de Bordeaux, Inserm, and Inria, Bordeaux, France.
Edouard LhommeBordeaux Population Health Research Centre, Université de Bordeaux, Inserm, and Inria, Bordeaux, France.
PREVAC study team

Funding

NCI NIH HHS HHSN261201500003CNCI NIH HHS HHSN261201500003INIAID NIH HHS HHSN272201800013C
6 · The paper itself

Abstract

rVSVΔG-ZEBOV-GP and Ad26.ZEBOV, MVA-BN-Filo are WHO-prequalified vaccination regimens against Ebola virus disease (EVD). Challenges associated with measuring long-term clinical protection warrant the evaluation of immune response kinetics after vaccination. Data from a large phase 2 randomized double-blind clinical trial (PREVAC) were used to evaluate waning of anti-Ebola virus (EBOV) glycoprotein (GP

Indexed as

Antibodies, ViralEbola VaccinesEbolavirusHemorrhagic Fever, EbolaImmunoglobulin GAdolescentAdultAntibody FormationChildChild, PreschoolDouble-Blind MethodFemaleHumansMaleMiddle AgedVaccinationAntibodies, ViralEbola VaccinesImmunoglobulin GantibodyEbola virus diseaseimmunogenicitymodellingvaccineWestern Africa

Identifiers

PMID39559990
PMCPMC11632942

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.